Pharming Group NV (PHAR) — Net Asset Quality Index
Pharming Group NV (PHAR) has a Net Asset Quality Index of 55.0% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $489.37 Million minus total liabilities of $220.41 Million yields net assets of $268.96 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check how resilient are Pharming Group NV's assets to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Pharming Group NV Net Asset Quality Index Over Time (2005–2025)
This chart shows how Pharming Group NV's Net Asset Quality Index has evolved across 21 annual periods from 2005 to 2025. As of March 2026, the index stands at 55.0%, representing net assets of $268.96 Million against total assets of $489.37 Million USD. See how liquid is Pharming Group NV's working capital to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Pharming Group NV (2005–2025)
The table below presents the year-by-year Net Asset Quality Index for Pharming Group NV from 2005 to 2025, covering 21 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see PHAR market cap.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 55.4% | $277.02 Million | $499.81 Million | $222.79 Million | ▲ +0.2 pp |
| 2024 | 55.3% | $221.06 Million | $399.99 Million | $178.92 Million | ▲ +8.0 pp |
| 2023 | 47.3% | $218.78 Million | $462.85 Million | $244.07 Million | ▼ -0.8 pp |
| 2022 | 48.1% | $204.64 Million | $425.80 Million | $221.16 Million | ▼ -0.5 pp |
| 2021 | 48.6% | $192.92 Million | $397.31 Million | $204.40 Million | ▲ +4.7 pp |
| 2020 | 43.8% | $150.16 Million | $342.55 Million | $192.39 Million | ▼ -2.0 pp |
| 2019 | 45.9% | $117.39 Million | $255.91 Million | $138.53 Million | ▲ +17.1 pp |
| 2018 | 28.8% | $70.64 Million | $245.45 Million | $174.81 Million | ▲ +17.5 pp |
| 2017 | 11.3% | $22.56 Million | $199.38 Million | $176.82 Million | ▼ -10.4 pp |
| 2016 | 21.7% | $28.89 Million | $133.34 Million | $104.45 Million | ▼ -19.7 pp |
| 2015 | 41.3% | $26.06 Million | $63.06 Million | $37.00 Million | ▼ -12.2 pp |
| 2014 | 53.6% | $36.29 Million | $67.75 Million | $31.46 Million | ▲ +37.6 pp |
| 2013 | 16.0% | $6.92 Million | $43.37 Million | $36.45 Million | ▲ +61.4 pp |
| 2012 | -45.4% | $-10.12 Million | $22.28 Million | $32.40 Million | ▼ -40.6 pp |
| 2011 | -4.8% | $-1.54 Million | $32.01 Million | $33.55 Million | ▼ -31.9 pp |
| 2010 | 27.1% | $13.43 Million | $49.59 Million | $36.16 Million | ▲ +3.3 pp |
| 2009 | 23.8% | $19.07 Million | $80.07 Million | $60.99 Million | ▲ +5.1 pp |
| 2008 | 18.7% | $17.45 Million | $93.40 Million | $75.96 Million | ▼ -11.7 pp |
| 2007 | 30.3% | $50.58 Million | $166.72 Million | $116.14 Million | ▼ -32.7 pp |
| 2006 | 63.0% | $65.78 Million | $104.37 Million | $38.59 Million | ▼ -20.1 pp |
| 2005 | 83.1% | $34.04 Million | $40.96 Million | $6.93 Million | — |